Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
Nov 30, 2017 Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
Nov 17, 2017 Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 7, 2017 Form 10-Q View HTML View PDF 375.0 KB Add to Briefcase
Mar 14, 2017 Form 10-K View HTML View PDF 809.4 KB Add to Briefcase
Add to Briefcase = add file to Briefcase